

LIGAND PHARMACEUTICALS INC
 Form 4
 November 22, 2006

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 MAIER PAUL V

2. Issuer Name and Ticker or Trading Symbol
 LIGAND PHARMACEUTICALS INC [LGND]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
 10275 SCIENCE CENTER DRIVE
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 11/20/2006

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 Sr. V-P, CFO

SAN DIEGO, CA 92121

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(D)	Price
Common Stock	11/20/2006		S		3,600	D	\$ 11.52
Common Stock	11/20/2006		S		100	D	\$ 11.51
Common Stock	11/20/2006		S		1,000	D	\$ 11.47
Common Stock	11/20/2006		S		1,000	D	\$ 11.4574
Common Stock	11/20/2006		S		1,000	D	\$ 11.4432

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

Common Stock	11/20/2006	M	27,016	A	\$ 9.25	105,267	D
Common Stock	11/20/2006	S	1,000	D	\$ 11.44	104,267	D
Common Stock	11/20/2006	S	1,000	D	\$ 11.4338	103,267	D
Common Stock	11/20/2006	S	1,000	D	\$ 11.4322	102,267	D
Common Stock	11/20/2006	S	100	D	\$ 11.43	102,167	D
Common Stock	11/20/2006	S	1,000	D	\$ 11.427	101,167	D
Common Stock	11/20/2006	S	1,000	D	\$ 11.4214	100,167	D
Common Stock	11/20/2006	S	3,500	D	\$ 11.42	96,667	D
Common Stock	11/20/2006	S	1,000	D	\$ 11.4132	95,667	D
Common Stock	11/20/2006	S	453	D	\$ 11.41	95,214	D
Common Stock	11/20/2006	S	5,163	D	\$ 11.4	90,051	D
Common Stock	11/20/2006	S	1,200	D	\$ 11.39	88,851	D
Common Stock	11/20/2006	S	800	D	\$ 11.38	88,051	D
Common Stock	11/20/2006	S	1,500	D	\$ 11.37	86,551	D
Common Stock	11/20/2006	S	1,600	D	\$ 11.36	84,951	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
--	------------------------------------	--------------------------------------	--	--------------------------------	---	--	---

